ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

ClinicalTrials.gov ID: NCT01851369

Public ClinicalTrials.gov record NCT01851369. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

Study identification

NCT ID
NCT01851369
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
93 participants

Conditions and interventions

Interventions

  • 5-HT3 antagonist Other
  • Aprepitant Other
  • Biopsy Procedure
  • CT scan Diagnostic Test
  • Lomotil Other
  • Metoclopramide Other
  • Prochlorperazine Other
  • TRC102 Drug

Other · Procedure · Diagnostic Test + 1 more

Eligibility (public fields only)

Age range
18 Years to 120 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 11, 2013
Primary completion
Jul 31, 2023
Completion
Jul 31, 2023
Last update posted
May 7, 2024

2013 – 2023

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
National Institutes of Health Clinical Center Bethesda Maryland 20892

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01851369, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2024 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01851369 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →